Quick Facts: Uses and Benefits

• Acute Anemia: Available as a therapeutic option for surgical patients experiencing acute anemia in certain countries.
• Oxygen Delivery: Acts as an oxygen-carrying agent to help provide oxygen to tissues.
• Blood Management: May reduce or delay the requirement for red blood cell transfusions in appropriate patients.

---

HEMOPURE is a therapeutic solution primarily studied for its application as an oxygen carrier. It has been the subject of research in clinical scenarios involving severe anemia where allogeneic blood transfusion is either not possible, contraindicated, or unavailable.

In some international jurisdictions, HEMOPURE is an approved therapeutic option for managing acute anemia in surgical patients, with the goal of eliminating, delaying, or reducing the need for allogeneic red blood cell administration. Its function is to temporarily increase the oxygen-carrying capacity of the blood to support tissue oxygenation.

In the United States, this product is considered an investigational new drug and is not approved for any human use. It is accessible only through specific pathways, such as the Expanded Access Program, for patients with life-threatening anemia who have exhausted other treatment alternatives.

Individual responses to this treatment can vary, and it is intended to serve as a temporary measure while the body has the opportunity to regenerate its own red blood cells.

HEMOPURE (Haemoglobin Glutamer) eligibility is strictly defined by regulatory criteria, particularly as an unapproved drug in the United States available only through the Expanded Access Program (EAP), or as an approved treatment for adult surgical patients in some countries (e.g., South Africa).

Populations for Whom Use is Prohibited or Restricted

Classification	Rule (Official Labeling/EAP)
Absolute Contraindication	Patients with known hypersensitivity or allergy to beef products (due to bovine origin).
General Exclusion	Patients who are eligible for standard red blood cell transfusions (Exclusion from EAP criteria).
Age-Based Restriction	Pediatric patients (under 18 years of age) are not approved for use.

Eligibility is highly restricted and subject to individual determination for patients with pre-existing conditions such as uncontrolled hypertension, circulatory hypervolemia, heart failure, renal failure, or systemic mastocytosis.

Use in Specific Populations

• Adults: The target population is generally adults (18 years and older).
• Older Adults: Patients over 80 years of age require special case-by-case determination.
• Pregnancy/Lactation: Use in pregnant or lactating patients is not established due to insufficient human safety data in official regulatory documents.

Interactions with other medicines and products

Hemopure (hemoglobin glutamer - 250 (bovine), or HBOC-201) is an investigational agent and is not approved by the U.S. Food and Drug Administration (FDA) for human use. Due to its status as an unapproved product in major global markets like the U.S. and Europe, it does not have an official, government-mandated label detailing established drug-drug interaction mechanisms and classifications, as would be standard for an approved medicine.

Interaction information is primarily derived from its use in clinical trials, the FDA Expanded Access Program (EAP), and approved regulatory documents from other countries.

Key Interaction Contexts

Category	Context/Note
Vasoactive Agents	HBOC-201 is known to cause a transient increase in blood pressure due to its inherent properties. This effect requires close clinical monitoring. Caution is exercised when administering Hemopure alongside other drugs that influence blood pressure, as its vasoactive effect may be cumulative or require adjustment of other pressor or antihypertensive medications.
Laboratory Interference	The presence of Hemopure in the bloodstream may interfere with certain laboratory tests that use spectrophotometric or optical methods, such as measurement of hemoglobin/hematocrit (Hct), partial thromboplastin time (aPTT), or prothrombin time (PT). These interferences are physical and must be accounted for by using alternative testing methodologies, such as mechanical or magnetic coagulation assays. Pulse oximetry readings (SpO2) may also be lower than actual oxygen saturation due to the product's characteristics.
Methemoglobin Reduction	An expected effect of Hemopure is a transient increase in methemoglobin (MetHb) levels. The use of agents such as ascorbic acid is recommended to help minimize MetHb formation, and methylene blue may be considered for higher levels, though this is avoided in patients with a known G6PD deficiency due to the risk of hemolysis.

Acellular Oxygen Transport and Delivery Dynamics

The core mechanism of Haemoglobin Glutamer (HBOC-201) is to directly increase the oxygen-carrying capacity of the plasma. The acellular haemoglobin readily binds molecular oxygen ( O2), and critically, its right-shifted O2 dissociation curve (high P50) dictates that it releases O2 more easily into peripheral tissues. This increased off-loading efficiency and the small size of the carrier molecules facilitate rapid O2 diffusion, resulting in elevated tissue PO2 (partial pressure of O2).

---

Modulation of Vascular Tone and Pressure

This domain involves the haemoglobin molecule's interaction with the vascular system as an NO scavenger. By reacting with and consuming endothelium-derived Nitric Oxide (,textNO), the drug functionally reduces this endogenous vasodilator's availability. This results in unopposed vasoconstriction, which is a mechanistic cascade that contributes to a transient increase in Systemic Vascular Resistance (SVR) and Mean Arterial Pressure (MAP).

---

Colloidal Plasma Volume Dynamics

The third mechanistic domain is physical, stemming from the drug's formulation as an iso-oncotic solution. The polymerized haemoglobin acts as a colloid, generating significant oncotic pressure. This physical pressure gradient is central to retaining fluid within the circulatory system, contributing to the retention and increase of the intravascular volume.

How to Use HEMOPURE — Official Administration Guidelines

The administration of HEMOPURE (Haemoglobin Glutamer (bovine)) is governed by specific instructions outlined in prescribing information. The product is intended for intravenous administration and requires strict adherence to dose and fluid management guidelines.

---

Administration Scope

Entity	Instruction
Route of administration	Intravenous (IV) Infusion via a standard line.
Dosing schedule	Initial Dose (Adults): 500 mL (2 units). Subsequent periodic infusions of 250 to 500 mL are determined by daily clinical assessment.
Preparation requirements	The solution is ready for immediate use and does not require reconstitution or special filters. It must not be frozen.
Age-group rules	Extreme caution and careful monitoring are required for administration to patients over 80 years of age.
Special procedural conditions	The conventional infusion rate is 8 mL/min, which must be adjusted to the patient’s condition. Total Hemoglobin (THb), not hematocrit, must be used for assessment.

---

Instruction Classifications (High-Level)

Classification	Specification
Administration method type	Intravenous (IV).
Frequency pattern	As-needed / Daily Assessment based on the product's half-life of approximately 19 hours.

---

Resulting Procedural Structure

The protocol mandates the intravenous route and the administration of the initial 500 mL dose. Use is structured around a daily assessment pattern, which guides the need for periodic re-dosing based on the patient's condition. The administration process strictly requires careful monitoring of circulatory volume and fluid balance due to the nature of the solution.

Research Evidence / Overview of studies for HEMOPURE

---

Research Evidence for Acute Anemia in Surgical Settings

The primary clinical research exploring Haemoglobin Glutamer (HEMOPURE) was studied for its use in adult patients facing significant blood loss, or acute anemia, during or after elective surgeries, such as cardiac or orthopedic procedures. This research includes Randomized Controlled Trials (RCTs) across multiple medical centers. These trials were designed to examine temporary physiological imbalance by measuring key outcomes related to systemic or functional imbalance. Specifically, researchers monitored if the solution was associated with a delay or reduction in the requirement for allogeneic red blood cell (RBC) transfusions.

In addition to transfusion patterns, the studies explored outcomes related to patient survival and changes in hemodynamic parameters, which describe how the blood flows and the heart functions. The findings describe patterns observed in the studies related to measured changes during the study period. While some trials described measurements of delayed RBC transfusion, regulatory reviews of the pooled data noted that results varied regarding the composite endpoints that compared the group receiving the solution to control groups. These varying results have led to different conclusions by health authorities around the world.

Research Evidence for Life-Threatening Anemia (Investigational Use)

The medicine was evaluated in a separate context involving patients with severe or life-threatening critical anemia (very low hemoglobin levels) who had no alternative treatment options, such as those who refused traditional blood products. In the United States, this use is tracked through Expanded Access Programs (EAP), which are considered investigational. The research in this setting is observational and non-randomized, primarily consisting of case reports and observational studies.

These studies monitored patients facing a sudden and acute lack of oxygen-carrying capacity. The outcomes research examined focused on overall patient survival and the resolution of critical symptoms linked to oxygen deprivation. Because these patients were studied for a short-term, life-critical episode, the findings were highly specific to individual cases or small groups of patients in extremis who had no standard treatment recourse.

Understanding the Certainty and Gaps in the Evidence

It is important to understand that the evidence quality varies across studies for Haemoglobin Glutamer. The research contributes to the broader evidence landscape by showing what has been observed so far in specific, acute settings. Key limitations in the overall research include the inconsistent findings noted in comparative studies and the fact that the follow-up durations were limited for fully understanding long-term patterns. The research provides context but not individual predictions, and the evidence highlights what is known — and what is still uncertain — about this type of oxygen-carrying solution.

Key Studies & References

1. Expanded Access Protocol to Provide Hemopure® (HBOC-201) for Patients in Need of Oxygen-Carrying Capacity When Blood Transfusions Are Not an Option

Common questions about HEMOPURE (FAQ)

---

Q: Is HEMOPURE used as a total replacement for blood?

Regulatory documents define HEMOPURE as a temporary and partial replacement for the oxygen-carrying capacity of red blood cells. It provides an oxygen bridge but does not replace all the essential functions of blood, such as clotting factors, immune components, or full volume maintenance.

Q: Can HEMOPURE be used for low red blood cell count (anemia) outside of surgery?

The product is generally indicated for acute, symptomatic, or life-threatening anemia in specific critical scenarios, especially when traditional blood transfusion is not an option. It is not approved for the treatment of general or chronic low red blood cell count.

Q: What medications are listed as having major interactions with HEMOPURE?

Regulatory context notes that caution is required when it is used alongside other drugs that influence blood pressure, such as antihypertensive medications, as the effects may be cumulative. Additionally, the use of other colloid solutions (volume expanders) is generally not recommended.

Q: What does the research say about HEMOPURE's use in trauma or emergency situations?

Studies and official information indicate that the product has been investigated in the context of acute trauma and hemorrhagic shock. This includes trials sponsored by groups like the U.S. Department of Defense to evaluate its potential use in pre-hospital and emergency settings.

Q: What kind of patient monitoring is required after receiving HEMOPURE?

Official guidelines outline the necessity of close patient monitoring after administration, including attention to circulatory volume and fluid balance. Monitoring includes careful attention to the patient’s blood pressure due to the transient risk of hypertension associated with its use.

Q: What is the shelf life of HEMOPURE compared to banked blood?

Official information states that HEMOPURE is stable at room temperature (between 2 C and 30 C) for up to 3 years. This compares to standard banked red blood cells, which typically require refrigeration and have a shelf life of approximately 42 days.

Q: How quickly does HEMOPURE start working after administration?

Due to its mechanism of action and immediate volume expansion properties, the hemodynamic effects, including changes in oxygen-carrying capacity and blood pressure, are observed rapidly during and immediately following the intravenous administration.

Q: Why are some people concerned about the risk of infection with blood products like HEMOPURE?

The product is manufactured from purified bovine hemoglobin and undergoes a rigorous process to remove diseases or pathogens, including viruses and prions. Official documents state that the finished product is described as being free of infectious agents.

Q: How does HEMOPURE compare to other oxygen-carrying solutions that were studied?

HEMOPURE (HBOC-201) is classified as a second-generation polymerized Hemoglobin-Based Oxygen Carrier (HBOC). It has been evaluated within this pharmacological class alongside other products designed to provide temporary oxygen support.

Q: What is the process for a hospital to obtain and use HEMOPURE?

In the United States, HEMOPURE is an investigational drug, meaning it is not generally approved for commercial use. It is primarily available only through qualifying clinical trials or the FDA's Expanded Access Program (EAP) for specific patients with severe, life-threatening anemia.

Q: Why is HEMOPURE sometimes mentioned in the context of military medicine?

Official documents and studies indicate the product has been evaluated in the context of military medicine. Trials sponsored by the U.S. Department of Defense have studied its potential use in trauma and pre-hospital settings where immediate access to blood transfusions is often limited.

How to Store and Dispose of HEMOPURE

Official regulatory documents require that HEMOPURE solution be stored at room temperature, specifically maintained between 2 C and 30 C (36 F to 86 F). It is a mandatory requirement that the product must not be frozen.

Stability and Handling

The solution is stable for up to 36 months when stored correctly. However, once the protective outer pouch is opened, the solution must be fully administered within 24 hours.

Disposal Requirements

Any portion of the solution remaining after the 24-hour stability period must be discarded. Disposal of the unused product and container must strictly comply with local regulations for pharmaceutical waste handling. As with all medicines, the product should be stored out of the sight and reach of children.